Genedrive (GB:GDR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genedrive PLC is set to release its preliminary results for the fiscal year ending June 2024, with a live presentation scheduled for December 2nd. The company is spearheading advancements in pharmacogenetic testing with innovative products like the Genedrive® MT-RNR1 and CYP2C19 ID Kits, which have been endorsed for use by the UK NHS to enhance patient care. With a strategy focusing on market growth and strategic expansions, Genedrive aims to solidify its position in the healthcare diagnostics sector.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
